Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.62 |
| ▸ | PDCD1LG2 | Q9BQ51 | 7/20 | 0.55 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24613605 | 0.81 | CD274 (0.44) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949648 | 0.80 | CD274 (0.56) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL21290731 | 0.77 | CD274 (1.00) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23961499 | 0.73 | CD274 (0.52) | CD274PDCD1PDCD1LG2NISCHKCNH2 | |
| SCHEMBL27079047 | 0.71 | CD274 (0.71) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL29982989 | 0.71 | CD274 (0.71) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL21507084 | 0.71 | CD274 (1.00) | CD274PDCD1PDCD1LG2NISCH | |
| SCHEMBL21291130 | 0.70 | CD274 (1.00) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL8199611 | 0.69 | NISCH (0.63) | NISCH | |
| SCHEMBL21289963 | 0.69 | CD274 (1.00) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885PDCD1LG2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.